Showing posts with label Infectious disease. Show all posts
Showing posts with label Infectious disease. Show all posts
Sunday, December 30, 2007
New Point-Of-Care Technology For Detecting Bloodstream Infections Unveiled
Researchers at the UC Davis Health System and Lawrence Livermore National Laboratory (LLNL) have entered into a collaborative effort to develop two ‘Point-Of-Care’ (POC) prototype instruments for the detection of pathogens causing bloodstream infections, one in hospital settings and the other, a field portable device, for disaster management camps. The team, led by Gerald Kost, Professor of Pathology and Laboratory Medicine, and Director of the Point-of-Care Testing Center for Teaching and Research (POCT-CTR), will develop these novel devices using the elementary technologies of other LLNL-developed instruments, such as the Autonomous Pathogen Detection System, designed for protection against bioterrorism. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has already granted a fund of around $8.5 million for the development of these devices.
Friday, December 28, 2007
Nutra Pharma Expands Licensing Agreement to Include Environmental Testing for Nontuberculous Mycobacterium
PRESS RELEASE
BOCA RATON, Fla., Dec 27, 2007 (BUSINESS WIRE) -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that it has expanded its licensing agreement with NanoLogix, Inc., (Pink Sheets: NNLX) to include intellectual property for the use of testing the environment for NonTuberculous Mycobacterium (NTM).
"NTM infections are becoming a major concern for hospitals and medical clinics around the world," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to attempt to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections," he added.
NonTuberculous Mycobacterium, also known as atypical Tuberculosis (Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a bacteria that is found in water, including hot tubs and showers, some domestic and wild animals, and soil. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex (MAC). This is a primary cause of respiratory disease in humans and is a leading cause of death in HIV/AIDS patients.
"Expanding this licensing agreement to include environmental testing is a natural progression of our relationship with Nutra Pharma and our belief in its ability to successfully bring these kits to market," commented Bret Barnhizer, President and CEO of NanoLogix, Inc. "In addition to helping detect NTM in patients, Nutra Pharma will now be able to test for NTM in the environment to help prevent others from becoming infected," he concluded.
Nutra Pharma's wholly-owned medical devices subsidiary, Designer Diagnostics, is currently planning to undergo third party validation for its NTM diagnostic test kits at leading Tuberculosis research institute, National Jewish Medical and Research Center, in Denver, Colorado. The Company plans to apply for FDA approval upon successful completion of this clinical trial.
Recently, distinguished NTM research scientist, Dr. Rahul Narang, used the Designer Diagnostics test kits to test soil and water samples collected from the environment of patients with NTM infections. This was the first time the technique was used in India and the findings were presented in November at the 38th Union World Conference on Lung Health in Cape Town, South Africa.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The expanded licensing agreement with NanoLogix, Inc., to include environmental testing should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE: Nutra Pharma Corp.
Nutra Pharma Corp.
David Isserman, 877-895-5647
ir@nutrapharma.comCopyright Business Wire 2007
BOCA RATON, Fla., Dec 27, 2007 (BUSINESS WIRE) -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that it has expanded its licensing agreement with NanoLogix, Inc., (Pink Sheets: NNLX) to include intellectual property for the use of testing the environment for NonTuberculous Mycobacterium (NTM).
"NTM infections are becoming a major concern for hospitals and medical clinics around the world," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to attempt to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections," he added.
NonTuberculous Mycobacterium, also known as atypical Tuberculosis (Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a bacteria that is found in water, including hot tubs and showers, some domestic and wild animals, and soil. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex (MAC). This is a primary cause of respiratory disease in humans and is a leading cause of death in HIV/AIDS patients.
"Expanding this licensing agreement to include environmental testing is a natural progression of our relationship with Nutra Pharma and our belief in its ability to successfully bring these kits to market," commented Bret Barnhizer, President and CEO of NanoLogix, Inc. "In addition to helping detect NTM in patients, Nutra Pharma will now be able to test for NTM in the environment to help prevent others from becoming infected," he concluded.
Nutra Pharma's wholly-owned medical devices subsidiary, Designer Diagnostics, is currently planning to undergo third party validation for its NTM diagnostic test kits at leading Tuberculosis research institute, National Jewish Medical and Research Center, in Denver, Colorado. The Company plans to apply for FDA approval upon successful completion of this clinical trial.
Recently, distinguished NTM research scientist, Dr. Rahul Narang, used the Designer Diagnostics test kits to test soil and water samples collected from the environment of patients with NTM infections. This was the first time the technique was used in India and the findings were presented in November at the 38th Union World Conference on Lung Health in Cape Town, South Africa.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The expanded licensing agreement with NanoLogix, Inc., to include environmental testing should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE: Nutra Pharma Corp.
Nutra Pharma Corp.
David Isserman, 877-895-5647
ir@nutrapharma.comCopyright Business Wire 2007
Sunday, June 3, 2007
Applied Biosystems/ U.S. Department of Defense Contract for Prototype Instrument System to Identify Infectious Diseases Terminated
System Met Technical Milestones; Parties Could Not Agree on Further Development and Commercialization
FOSTER CITY, Calif.--(BUSINESS WIRE)--Applied Biosystems (NYSE:ABI), an Applera Corporation business, announced today that its contract with the U.S. Department of Defense surrounding the development of a prototype instrument system to improve the way infectious diseases are identified for epidemiological and biosecurity purposes has been terminated for the convenience of the government. Though Applied Biosystems had successfully completed all technical milestones required to date in the contract, the action was taken by the government after Applied Biosystems and the U.S. Air Force were unable to agree on an approach for further development and commercialization of an instrument system that could be derived from an AB prototype instrument. Applied Biosystems anticipates no material financial impact from the contract termination.
Applied Biosystems expects that its biosecurity strategy will continue to focus on delivering early warning systems for detecting and tracking emerging natural and man-made pathogens in the environment, in agriculture, and in the animal and human food supply.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers. Celera maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking to develop therapeutic products based on these discovered targets through strategic partnerships.
Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923.
Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Applied Biosystems (NYSE:ABI), an Applera Corporation business, announced today that its contract with the U.S. Department of Defense surrounding the development of a prototype instrument system to improve the way infectious diseases are identified for epidemiological and biosecurity purposes has been terminated for the convenience of the government. Though Applied Biosystems had successfully completed all technical milestones required to date in the contract, the action was taken by the government after Applied Biosystems and the U.S. Air Force were unable to agree on an approach for further development and commercialization of an instrument system that could be derived from an AB prototype instrument. Applied Biosystems anticipates no material financial impact from the contract termination.
Applied Biosystems expects that its biosecurity strategy will continue to focus on delivering early warning systems for detecting and tracking emerging natural and man-made pathogens in the environment, in agriculture, and in the animal and human food supply.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers. Celera maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking to develop therapeutic products based on these discovered targets through strategic partnerships.
Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923.
Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
Subscribe to:
Posts (Atom)
